Navigate the Synta Pharma SNTA Research Notes Pages
- Introduction (valuation, financials, outlooks, catalysts)
- Ganetespib - Background (HSP90, basic drug info, regulatory strategies and business development)
- Ganetespib - HSP90 inhibitor safety and toxicity (info on liver and ocular toxicities associated with this class of drugs)
- Ganetespib - NSCLC (lead programs in lung cancer including ALK+ group and combo w/ docetaxel)
- Ganetespib - Clinical Trials (complete list of trials in other indications and links to data presentations)
- Elesclomol & Pipeline (information about other drug candidates in the SNTA pipeline)
- HSP90 Inhibitors - learn more about targeting heat shock protein 90 and all inhibitors in development